Cover Image
市場調查報告書

組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363131
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析 Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 110 Pages
簡介

本報告提供組蛋白去乙醯酶1 (EC 3.5.1.98)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0601TDB

Summary

Global Markets Direct's, 'Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Overview 8
  • Therapeutics Development 9
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Stage of Development 9
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Therapy Area 10
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Indication 11
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Products Glance 13
  • Late Stage Products 13
  • Early Stage Products 14
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Companies 15
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Universities/Institutes 21
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment 23
  • Assessment by Monotherapy/Combination Products 23
  • Assessment by Mechanism of Action 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29
  • 4SC AG 29
  • Acetylon Pharmaceuticals, Inc. 30
  • Chipscreen Biosciences Ltd 31
  • Curis, Inc. 32
  • GlaxoSmithKline Plc 33
  • HitGen LTD 34
  • IRBM Science Park SpA 35
  • Italfarmaco S.p.A. 36
  • MEI Pharma, Inc. 37
  • Merck & Co., Inc. 38
  • Mirati Therapeutics Inc. 39
  • Oncolys BioPharma Inc 40
  • Sigma-Tau S.p.A. 41
  • Syndax Pharmaceuticals Inc 42
  • TetraLogic Pharmaceuticals 43
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles 44
  • 4SC-202 - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • ACY-738 - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • ACY-957 - Drug Profile 48
  • Product Description 48
  • Mechanism Of Action 48
  • R&D Progress 48
  • crocetin - Drug Profile 50
  • Product Description 50
  • Mechanism Of Action 50
  • R&D Progress 50
  • CS-3158 - Drug Profile 51
  • Product Description 51
  • Mechanism Of Action 51
  • R&D Progress 51
  • CUDC-907 - Drug Profile 52
  • Product Description 52
  • Mechanism Of Action 52
  • R&D Progress 52
  • entinostat - Drug Profile 57
  • Product Description 57
  • Mechanism Of Action 57
  • R&D Progress 57
  • givinostat - Drug Profile 64
  • Product Description 64
  • Mechanism Of Action 64
  • R&D Progress 64
  • HG-3001 - Drug Profile 66
  • Product Description 66
  • Mechanism Of Action 66
  • R&D Progress 66
  • Largazole - Drug Profile 67
  • Product Description 67
  • Mechanism Of Action 67
  • R&D Progress 67
  • mocetinostat - Drug Profile 68
  • Product Description 68
  • Mechanism Of Action 68
  • R&D Progress 68
  • OBP-801 - Drug Profile 73
  • Product Description 73
  • Mechanism Of Action 73
  • R&D Progress 73
  • pracinostat - Drug Profile 74
  • Product Description 74
  • Mechanism Of Action 74
  • R&D Progress 74
  • remetinostat - Drug Profile 80
  • Product Description 80
  • Mechanism Of Action 80
  • R&D Progress 80
  • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 82
  • Product Description 82
  • Mechanism Of Action 82
  • R&D Progress 82
  • Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 83
  • Product Description 83
  • Mechanism Of Action 83
  • R&D Progress 83
  • Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 84
  • Product Description 84
  • Mechanism Of Action 84
  • R&D Progress 84
  • Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile 85
  • Product Description 85
  • Mechanism Of Action 85
  • R&D Progress 85
  • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 86
  • Product Description 86
  • Mechanism Of Action 86
  • R&D Progress 86
  • ST-3595 - Drug Profile 87
  • Product Description 87
  • Mechanism Of Action 87
  • R&D Progress 87
  • tucidinostat - Drug Profile 88
  • Product Description 88
  • Mechanism Of Action 88
  • R&D Progress 88
  • vorinostat - Drug Profile 91
  • Product Description 91
  • Mechanism Of Action 91
  • R&D Progress 91
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Projects 95
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Featured News & Press Releases 99
  • Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy 99
  • Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 99
  • Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program 100
  • Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 100
  • May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 100
  • May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 101
  • Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 102
  • Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 104
  • Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 104
  • Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting 104
  • Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 105
  • Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 105
  • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 106
  • Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 106
  • Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 107
  • Appendix 109
  • Methodology 109
  • Coverage 109
  • Secondary Research 109
  • Primary Research 109
  • Expert Panel Validation 109
  • Contact Us 109
  • Disclaimer 110

List of Tables

  • Number of Products under Development for, H2 2016 9
  • Number of Products under Development by Therapy Area, H2 2016 10
  • Number of Products under Development by Indication, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 13
  • Comparative Analysis by Early Stage Products, H2 2016 14
  • Number of Products under Development by Companies, H2 2016 15
  • Products under Development by Companies, H2 2016 16
  • Products under Development by Companies, H2 2016 (Contd..1) 17
  • Products under Development by Companies, H2 2016 (Contd..2) 18
  • Products under Development by Companies, H2 2016 (Contd..3) 19
  • Products under Development by Companies, H2 2016 (Contd..4) 20
  • Number of Products under Investigation by Universities/Institutes, H2 2016 21
  • Products under Investigation by Universities/Institutes, H2 2016 22
  • Assessment by Monotherapy/Combination Products, H2 2016 23
  • Number of Products by Stage and Mechanism of Action, H2 2016 24
  • Number of Products by Stage and Route of Administration, H2 2016 26
  • Number of Products by Stage and Molecule Type, H2 2016 28
  • Pipeline by 4SC AG, H2 2016 29
  • Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 30
  • Pipeline by Chipscreen Biosciences Ltd, H2 2016 31
  • Pipeline by Curis, Inc., H2 2016 32
  • Pipeline by GlaxoSmithKline Plc, H2 2016 33
  • Pipeline by HitGen LTD, H2 2016 34
  • Pipeline by IRBM Science Park SpA, H2 2016 35
  • Pipeline by Italfarmaco S.p.A., H2 2016 36
  • Pipeline by MEI Pharma, Inc., H2 2016 37
  • Pipeline by Merck & Co., Inc., H2 2016 38
  • Pipeline by Mirati Therapeutics Inc., H2 2016 39
  • Pipeline by Oncolys BioPharma Inc, H2 2016 40
  • Pipeline by Sigma-Tau S.p.A., H2 2016 41
  • Pipeline by Syndax Pharmaceuticals Inc, H2 2016 42
  • Pipeline by TetraLogic Pharmaceuticals, H2 2016 43
  • Dormant Projects, H2 2016 95
  • Dormant Projects (Contd..1), H2 2016 96
  • Dormant Projects (Contd..2), H2 2016 97
  • Dormant Projects (Contd..3), H2 2016 98

List of Figures

  • Number of Products under Development for, H2 2016 9
  • Number of Products under Development by Therapy Area, H2 2016 10
  • Number of Products under Development by Top 10 Indication, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 13
  • Comparative Analysis by Early Stage Products, H2 2016 14
  • Assessment by Monotherapy/Combination Products, H2 2016 23
  • Number of Products by Stage and Mechanism of Actions, H2 2016 24
  • Number of Products by Routes of Administration, H2 2016 25
  • Number of Products by Stage and Routes of Administration, H2 2016 25
  • Number of Products by Molecule Types, H2 2016 27
  • Number of Products by Stage and Molecule Type, H2 2016 27
Back to Top